ArticleIJID regions2026
First laboratory-confirmed fatal dengue virus infection and its implications for national arboviral surveillance in Liberia.
Article in IJID regions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Dengue virus (DENV) is an emerging public health threat in Africa, where its impact is underestimated due to nonspecific clinical manifestations and restricted diagnostic capabilities. In Liberia, laboratory-confirmed cases of DENV were initially recorded in an urban febrile surveillance study (2018-2020), yet severe or fatal outcomes had not been previously reported. This paper reports the first laboratory-confirmed fatal dengue case and its implications for national surveillance and policy in Liberia. Case report: On February 2, 2026, a 38-year-old Liberian man arrived at J. J. Dossen Memorial Hospital in Maryland County, located in the southern region of Liberia, with a 2-day history of high fever, severe headache, myalgia, weakness, and abdominal discomfort. He had no recent history of travel. The first laboratory investigation using a rapid test and microscopy ruled out malaria. Molecular detection performed at the National Public Health Reference Laboratory was negative for Lassa, Ebola, and Marburg. Despite management with supportive care, his condition deteriorated clinically upon readmission, and the patient died on February 6, 2026. Serological testing performed at MDS-Lancet Laboratories, Ghana detected DENV immunoglobulin G antibodies and yielded a positive nonstructural protein 1 antigen result, prompting further investigations. Consequently, a blood sample was referred to the Institut Pasteur de Dakar, Senegal, where confirmatory testing was conducted to include differential reverse transcription polymerase chain reaction for a diverse array of arboviruses and viral hemorrhagic fevers and differential virus-specific immunoglobulin M (IgM) enzyme-linked immunosorbent assay. The sample tested positive for DENV ribonucleic acid by reverse transcription polymerase chain reaction, negative for other viruses, and negative for dengue-specific IgM. The absence of detectable IgM may reflect specimen collection during an early stage of infection before seroconversion. However, IgM negativity alone cannot distinguish between primary and secondary infection. Conclusion: This is the first molecular confirmation of fatal dengue in Liberia. It highlights the potential for severe outcomes and suggests locally acquired transmission in southeastern Liberia, a region bordering Côte d'Ivoire. There is a critical need for swift implementation of integrated arboviral surveillance in both urban and rural settings, better diagnostic capabilities, and possibly a nationwide seroepidemiological study to estimate the actual burden of dengue in the country.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.